Healios KK (4593) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fuji Pharma Co., Ltd.

Koa Shoji Holdings Co., Ltd.

Elan Corp.

Taiko Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd.

CellSource Co., Ltd.

Noile-Immune Biotech, Inc.

Seikagaku Corp.

Healios KK

Fuso Pharmaceutical Industries Ltd.

SanBio Co., Ltd.

Why is Healios KK ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate 6.63% of over the last 5 years

INTEREST(HY) At JPY 3,629 MM has Grown at 72.81%
NET SALES(Q) At JPY 22 MM has Fallen at -85.03%
PRE-TAX PROFIT(Q) At JPY -2,125 MM has Fallen at -105.96%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 86.34%, its profits have risen by 20.7%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Healios KK for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Healios KK

66.67%

1.16

88.62%

Japan Nikkei 225

28.54%

1.14

25.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

142.58%

EBIT Growth (5y)

6.63%

EBIT to Interest (avg)

-4.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.69

Sales to Capital Employed (avg)

0.06

Tax Ratio

5.82%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

22.44

EV to EBIT

-15.49

EV to EBITDA

-17.44

EV to Capital Employed

-30.25

EV to Sales

68.99

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-223.43%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at JPY -2,296 MM

NET PROFIT(9M)

Higher at JPY -4,453 MM

DEBT-EQUITY RATIO (HY)

Lowest at -290.04 %

-35What is not working for the Company

INTEREST(HY)

At JPY 3,629 MM has Grown at 72.81%

NET SALES(Q)

At JPY 22 MM has Fallen at -85.03%

PRE-TAX PROFIT(Q)

At JPY -2,125 MM has Fallen at -105.96%

NET PROFIT(Q)

At JPY -2,148 MM has Fallen at -96.52%

ROCE(HY)

Lowest at -266.1%

RAW MATERIAL COST(Y)

Grown by 825.97% (YoY

CASH AND EQV(HY)

Lowest at JPY 11,708 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.32%

OPERATING PROFIT(Q)

Lowest at JPY -798 MM

Here's what is working for Healios KK

Operating Cash Flow

Highest at JPY -2,296 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JPY MM)

Debt-Equity Ratio

Lowest at -290.04 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Healios KK

Interest

At JPY 3,629 MM has Grown at 72.81%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales

At JPY 22 MM has Fallen at -85.03%

over average net sales of the previous four periods of JPY 147 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY -2,125 MM has Fallen at -105.96%

over average net sales of the previous four periods of JPY -1,031.75 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -2,148 MM has Fallen at -96.52%

over average net sales of the previous four periods of JPY -1,093 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Operating Profit

Lowest at JPY -798 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Cash and Eqv

Lowest at JPY 11,708 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 0.32%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 825.97% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales